# Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

> **NCT06399029** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Zurich** · enrollment: 22 (actual)

## Conditions studied

- Exanthema
- Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy

## Interventions

- **DRUG:** Ruxolitinib Topical Cream

## Key facts

- **NCT ID:** NCT06399029
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06399029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06399029, "Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06399029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*